ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

AADI Aadi Bioscience Inc

1.6697
-0.0103 (-0.61%)
Last Updated: 11:02:26
Delayed by 15 minutes

Period:

Draw Mode:

Volume 36,416
Bid Price 1.66
Ask Price 1.67
News -
Day High 1.705

Low
1.55

52 Week Range

High
8.60

Day Low 1.66
Company Name Stock Ticker Symbol Market Type
Aadi Bioscience Inc AADI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0103 -0.61% 1.6697 11:02:26
Open Price Low Price High Price Close Price Prev Close
1.67 1.66 1.705 1.68
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
273 36,416 $ 1.67 $ 60,962 - 1.55 - 8.60
Last Trade Time Type Quantity Stock Price Currency
11:03:42 11 $ 1.66 USD

Aadi Bioscience Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
40.76M 24.55M - 24.35M -65.77M -2.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aadi Bioscience News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AADI Message Board. Create One! See More Posts on AADI Message Board See More Message Board Posts

Historical AADI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.781.961.661.81132,727-0.1103-6.20%
1 Month2.322.371.662.01186,877-0.6503-28.03%
3 Months1.772.471.662.10351,016-0.1003-5.67%
6 Months4.245.701.552.36376,194-2.57-60.62%
1 Year8.008.601.553.36252,483-6.33-79.13%
3 Years30.0032.991.559.32174,806-28.33-94.43%
5 Years30.0032.991.559.32174,806-28.33-94.43%

Aadi Bioscience Description

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

Your Recent History

Delayed Upgrade Clock